Enhanced Group Applauds FDA Advisory Committee Recommendation Supporting Regulated Access to Therapeutic Peptides
Enhanced Group Inc. (NYSE: ENHA), a company focused on elite sports performance, personalized health optimization, and evidence-based longevity solutions, has welcomed a significant regulatory development following a recent vote by the U.S. Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC). The committee recommended that six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—be added to the FDA’s Section 503A Bulk Drug Substances List, a move that could eventually establish a legal and regulated pathway for licensed U.S. compounding pharmacies to prepare these substances for patients under physician supervision.
While the recommendation does not immediately authorize compounding of these peptides, it represents an important milestone in the ongoing effort to bring greater regulatory oversight, quality assurance, and transparency to a rapidly growing segment of personalized medicine. Enhanced Group believes the committee’s recommendation lays the groundwork for replacing largely unregulated distribution channels with a physician-directed, pharmacy-based model that prioritizes patient safety, product quality, and responsible clinical use.
Advisory Committee Recommends Six Peptides for the 503A Bulks List
During meetings held on July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend the inclusion of six peptide compounds on the Section 503A Bulk Drug Substances List:
- BPC-157
- KPV
- TB-500
- MOTS-c
- Epitalon
- Semax
If ultimately adopted by the FDA following the required rulemaking process, licensed 503A compounding pharmacies would be permitted to compound these substances under federal regulations and applicable state pharmacy laws when prescribed by authorized healthcare providers.
The recommendation reflects months of scientific review, expert testimony, and public comment submitted by stakeholders across healthcare, academia, pharmacy, and industry.
Enhanced described the committee’s decision as an encouraging step toward improving regulatory clarity for therapeutic peptides that have attracted growing interest in areas including tissue recovery, inflammation, metabolic health, and neurological research.
Moving Toward a Regulated Market
According to Enhanced Group, the peptide market has historically operated in an uncertain regulatory environment.
Many consumers seeking products such as BPC-157 or TB-500 have relied on online vendors operating outside traditional pharmaceutical oversight. In many cases, these products have not been subject to standardized manufacturing practices, quality testing, sterility requirements, or physician supervision.
The company believes that allowing licensed compounding pharmacies to prepare eligible peptides under FDA-recognized standards would help shift the marketplace toward greater accountability.
Instead of obtaining products through anonymous internet suppliers, patients could potentially receive physician-prescribed therapies prepared by licensed pharmacists operating within established regulatory frameworks.
Enhanced believes such a transition would improve patient confidence by promoting:
- Higher manufacturing standards
- Greater product traceability
- Improved quality assurance
- Physician oversight
- Pharmacy accountability
- Prescription-based access
CEO Highlights Regulatory Progress
Maximilian Martin, Co-Founder and Chief Executive Officer of Enhanced Group, described the committee’s recommendation as an important development for the peptide industry.
He noted that the advisory committee carefully evaluated available scientific evidence and engaged with expert testimony before reaching its recommendation.
According to Martin, the committee’s actions demonstrate a willingness to move away from regulatory uncertainty and toward a framework that encourages responsible oversight.
He emphasized that regulated access through licensed U.S. compounding pharmacies has long represented the company’s preferred model for making peptide therapies available under appropriate medical supervision.
Understanding the Regulatory Process
Although the committee’s vote represents meaningful progress, Enhanced emphasized that the recommendation is not yet a final FDA decision.
The Pharmacy Compounding Advisory Committee serves in an advisory capacity, providing scientific recommendations to the FDA.
Before these peptides can officially be included on the Section 503A Bulks List, the FDA must complete the federal notice-and-comment rulemaking process.
This process generally involves:
- FDA review of committee recommendations
- Publication of proposed regulatory language
- Public comment period
- Evaluation of submitted feedback
- Final agency determination
Industry observers estimate that completion of this process may require several months.
Historically, the FDA has frequently adopted recommendations issued by the Pharmacy Compounding Advisory Committee, although the agency retains final decision-making authority.
Enhanced Has Long Supported Regulated Access
Enhanced noted that it has consistently advocated for peptide access through licensed compounding pharmacies rather than through unregulated online suppliers.
The company recently submitted a formal comment letter supporting expansion of the 503A pathway.
The submission was co-signed by members of Enhanced’s Independent Medical Commission and reflected the organization’s longstanding position that physician-directed prescribing and pharmacy compounding provide the safest framework for peptide therapies.
Management believes regulated access offers significant advantages over existing gray-market distribution channels by establishing clear quality standards and professional medical oversight.
Existing Infrastructure Positions Company for Growth
Enhanced also highlighted that its operating model has been built around licensed U.S. compounding pharmacies since the company’s inception.
Rather than relying on unregulated suppliers, the company has developed relationships with both 503A and 503B compounding pharmacies while integrating physician oversight into its clinical care model.
If the FDA ultimately adopts the committee’s recommendations, management believes the company will be well positioned to rapidly expand its offerings through its existing infrastructure.
This infrastructure includes:
- Licensed pharmacy partnerships
- Medical oversight programs
- Clinical protocol development
- Prescription management
- Patient education
- Telehealth capabilities
The company believes these established relationships could allow efficient implementation once the regulatory pathway is finalized.
Expanding Through the Live Enhanced Platform
Enhanced also plans to utilize its Live Enhanced telehealth platform as an important component of future patient access.
Through physician consultations conducted via telehealth, eligible patients could potentially receive individualized evaluations before receiving compounded peptide therapies, assuming future regulatory approval.
The company believes combining physician assessment with licensed pharmacy compounding creates a compliant model that prioritizes patient safety while supporting personalized treatment strategies.
Focus on Personalized Therapeutic Protocols
Beyond access to individual peptides, Enhanced believes the future of peptide medicine lies in personalized combination therapies.
Management noted that discussions during the advisory committee meetings extended beyond individual substances and also considered how physicians may ultimately incorporate multiple peptides into individualized treatment plans.
Rather than promoting standardized treatment regimens, the company intends to emphasize physician-directed protocols tailored to each patient’s unique health profile and therapeutic goals.
Proposed Combination Protocols
Subject to future regulatory authorization, Enhanced plans to develop several combination protocols that integrate multiple peptides.
Among those proposed are:
Wolverine Stack
The Wolverine Stack combines:
- BPC-157
- TB-500
The company believes this combination may support tissue repair and soft-tissue recovery while appealing to physically active individuals seeking physician-directed recovery strategies.
GLOW Stack
The GLOW Stack expands upon the Wolverine combination by incorporating:
- BPC-157
- TB-500
- GHK-Cu
According to the company, this protocol is intended to integrate tissue support with collagen-related applications and skin-focused therapeutic objectives.
KLOW Stack
The KLOW Stack combines:
- BPC-157
- TB-500
- GHK-Cu
- KPV
Enhanced describes this broader protocol as incorporating additional anti-inflammatory support while addressing multiple physiological systems simultaneously.
The company emphasizes that any future protocols would be prescribed only following physician evaluation and individualized treatment planning, if permitted under applicable regulations.
Personalization as a Core Strategy
Enhanced believes personalization—not simply peptide availability—will distinguish future providers within the evolving market.
According to management, the company’s medical and scientific advisory teams have developed expertise in designing individualized therapeutic strategies based on factors including:
- Baseline health status
- Medical history
- Recovery needs
- Performance objectives
- Ongoing clinical assessment
- Treatment response over time
Rather than viewing therapy as static, the company believes treatment protocols should evolve alongside patients’ changing clinical conditions.
Management argues that personalized dosing, monitoring, and protocol adjustments represent a more sophisticated approach than standardized prescribing.
Preparing for Future Opportunities
Martin noted that Enhanced has built its business assuming increased regulatory oversight would eventually emerge across longevity medicine and peptide therapeutics.
As regulatory frameworks continue developing, the company intends to align its clinical operations with evolving FDA expectations while maintaining high standards for physician oversight and patient care.
Management also referenced the company’s experience implementing medically supervised protocols during activities associated with the Enhanced Games, stating that those experiences have contributed to the development of its clinical infrastructure.
Although additional regulatory steps remain before any changes become effective, Enhanced believes the Pharmacy Compounding Advisory Committee’s recommendation represents meaningful progress toward establishing a more transparent and medically supervised peptide marketplace in the United States.
Should the FDA complete the required rulemaking process and formally add BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax to the Section 503A Bulk Drug Substances List, licensed compounding pharmacies would gain a regulated pathway to prepare these substances under physician prescription and professional pharmacy oversight.
For Enhanced Group, the recommendation validates a business strategy centered on compliance, medical supervision, and individualized care. The company believes its established pharmacy relationships, telehealth infrastructure, clinical expertise, and focus on personalized therapeutic protocols position it to participate effectively in a future regulated peptide market while supporting patient safety, quality assurance, and responsible clinical practice.
About Enhanced Group, Inc.
Enhanced (NYSE: ENHA) is an elite sports competition and performance products company committed to giving athletes and people alike access to products and protocols that optimize health, performance, and recovery, through its Enhanced Games, Enhanced Breakers series events and its Live Enhanced consumer telehealth platform.